GlassScriptPhysician profile
Michael A Pablos Quiles
NPI 1841738291
$3,201.58
in general payments reported to CMS, 2019-2025
21 companies · $1,075 in 2025
The $1,075 reported for 2025 was more than what 79% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $68.04 · 2020: $83.26 · 2021: $123 · 2022: $548 · 2023: $701 · 2024: $604 · 2025: $1,075.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,379.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,379.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aurinia Pharma U.S., INC. | $583.77 | 2024-2025 | Lupkynis |
| Bayer Healthcare Pharmaceuticals INC. | $476.66 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $448.64 | 2019-2023 | Xarelto |
| Ardelyx, INC. | $254.80 | 2024-2025 | Ibsrela, Xphozah 30 Mg |
| Travere Therapeutics, INC. | $250.71 | 2023-2025 | Filspari |
| Otsuka America Pharmaceutical, INC. | $236.97 | 2023-2024 | Jynarque |
| Astrazeneca Pharmaceuticals LP | $171.52 | 2019-2023 | Lokelma |
| Mylan Specialty L.P. | $125.00 | 2023 | Yupelri |
| Boston Scientific Corporation | $122.16 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $115.39 | 2023 | |
| Veloxis Pharmaceuticals, INC. | $94.45 | 2025 | Envarsus |
| Takeda Pharmaceuticals U.S.A., INC. | $92.19 | 2024-2025 | Livtencity |
| Merck Sharp & Dohme LLC | $61.73 | 2024-2025 | Prevymis, Zerbaxa |
| Alexion Pharmaceuticals, INC. | $34.01 | 2024 | Ultomiris |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $23.30 | 2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Opko Pharmaceuticals, LLC | $22.14 | 2024 | Rayaldee |
| Apellis Pharmaceuticals, INC. | $19.91 | 2025 | Empaveli |
| Novartis Pharmaceuticals Corporation | $18.00 | 2022 | |
| Pbg Puerto Rico LLC | $17.88 | 2023 | |
| Pfizer INC. | $17.58 | 2021 | |
| Paratek Pharmaceuticals, INC. | $14.77 | 2024 | Nuzyra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Pablos Quiles listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.